Live Breaking News & Updates on Activity Across Activating Mutations

Stay updated with breaking news from Activity across activating mutations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki ....

United States , San Diego , Andrew Robbins , Christi Waarich , Cogent Biosciences Inc , Company Erb , Cogent Research Team , American Association For Cancer Research , American Association , Cancer Research , Chief Executive , Novel Mutant Selective , Activity Across Activating Mutations , Drug Design , Poster Section , Board Number , Abstract Number , Cogent Biosciences , Private Securities Litigation Reform Act , Annual Report , Novel Therapies , Isease Populations , Forward Looking Statements , Tyrosine Kinase Inhibitor , Biotechnology Company ,